COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HXB
|
|||
| Drug Name |
Lopinavir + ritonavir + interferon beta
|
|||
| Synonyms |
Aluviran + norvir + interferon beta
|
|||
| Drug Type |
Combination drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [2] |
| Lopinavir/ritonavir blocks viral replication of MERS-CoV via inhibiting the 3C-like protease (3CLpro). | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. | |||
| 2 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.